PENN Biomarker Core of the Alzheimer’s Disease Neuroimaging Initiative
- 1 December 2007
- journal article
- review article
- Published by S. Karger AG in Neurosignals
- Vol. 16 (1), 19-23
- https://doi.org/10.1159/000109755
Abstract
There is a pressing need to develop effective prevention and disease-modifying treatments for Alzheimer’s disease (AD), a dreaded affliction whose incidence increases almost logarithmically with age starting at about 65 years. A key need in the field of AD research is the validation of imaging and biochemical biomarkers. Biomarker tests that are shown to reliably predict the disease before it is clinically expressed would permit testing of new therapeutics at the earliest time point possible in order to give the best chance for delaying the onset of dementia in these patients. In this review the current state of AD biochemical biomarker research is discussed. A new set of guidelines for the diagnosis of AD in the research setting places emphasis on the inclusion of selected imaging and biochemical biomarkers, in addition to neuropsychological behavioral testing. Importantly, the revised guidelines were developed to identify patients at the earliest stages prior to full-blown dementia as well as patients with the full spectrum of the disease. The Alzheimer’s Disease Neuroimaging Initiative is a multicenter consortium study that includes as one of its primary goals the development of standardized neuroimaging and biochemical biomarker methods for AD clinical trials, as well as using these to measure changes over time in mildly cognitively impaired patients who convert to AD as compared to the natural variability of these in control subjects and their further change over time in AD patients. Validation of the biomarker results by correlation analyses with neuropsychological and neurobehavioral test data is one of the primary outcomes of this study. This validation data will hopefully provide biomarker test performance needed for effective measurement of the efficacy of new treatment and prevention therapeutic agents.Keywords
This publication has 20 references indexed in Scilit:
- Biomarkers of neurodegeneration for diagnosis and monitoring therapeuticsNature Reviews Drug Discovery, 2007
- Diagnosis and treatment of Parkinson disease: molecules to medicineJCI Insight, 2006
- Frontotemporal dementia: Clinicopathological correlationsAnnals of Neurology, 2006
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up studyThe Lancet Neurology, 2006
- NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic ImplicationsAnnual review of pathology, 2006
- The Role of Biomarkers in Clinical Trials for Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2006
- Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseasesNature, 2004
- Apolipoprotein E 4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and AgingCMAJ : Canadian Medical Association Journal, 2004
- Biological markers for therapeutic trials in Alzheimer’s disease: Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s diseaseNeurobiology of Aging, 2003
- Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's DiseaseNew England Journal of Medicine, 2002